Peptide Synthesis and Common Impurities: Deletions, Truncations, Oxidation and Deamidation
The short answer
Synthetic peptides are commonly assembled one amino-acid residue at a time. Each coupling, deprotection, washing, cleavage and purification step can introduce or fail to remove related substances. Later handling and storage can create additional degradation products.
A single chromatographic purity number does not identify every impurity. Understanding likely chemical pathways helps laboratories choose methods that separate, detect and characterize the material appropriately.
How solid-phase peptide synthesis works
In solid-phase peptide synthesis, the growing chain is attached to an insoluble support. Protected amino-acid derivatives are coupled sequentially, with deprotection and washing between cycles. After assembly, the peptide is cleaved from the support, side-chain protections are removed and the crude mixture is purified.
The approach enables automation and repeated reagent excess, but no chemical step is perfectly complete in every molecule.
Deletion sequences
If a coupling step is incomplete and an unreacted chain continues through later cycles, the final product can lack one or more intended residues. These deletion sequences may have masses close to the target and may co-elute under an insufficiently selective chromatographic method.
Truncations and incomplete products
Chains can terminate early because of incomplete reactions, capping, cleavage or difficult sequence-dependent chemistry. A truncated peptide shares part of the intended sequence but is a different molecular material. Biological evidence for the target sequence cannot be assigned automatically to the truncation.
Insertions, substitutions and stereochemical variants
Carryover, reagent contamination, incorrect building blocks or side reactions can produce insertion or substitution variants. Epimerization can convert an intended L-amino-acid configuration at a residue into a stereochemical variant without changing elemental composition in a way that ordinary mass measurement can easily distinguish.
Orthogonal separation and sequence-sensitive methods may be needed for these difficult impurities.
Oxidation
Oxidation can affect residues including methionine, cysteine, tryptophan and histidine, depending on sequence and conditions. Oxygen, light, reactive impurities and trace metals can contribute. Oxidation changes molecular structure and may alter chromatographic behaviour, binding or activity.
Deamidation and other degradation pathways
Asparagine and glutamine residues can undergo deamidation in sequence- and condition-dependent ways. Hydrolysis, disulfide scrambling, isomerization and aggregation may also occur. Temperature, pH, moisture, light and formulation influence which pathways dominate.
An impurity formed during synthesis and the same nominal modification formed during storage can still require context-specific investigation.
Process-related and non-peptide components
Residual solvents, reagents, scavengers, counter-ions, water and inorganic material are different from peptide-related sequence impurities. Some may not appear in a UV chromatogram. Their assessment requires methods suited to the attribute being measured.
Why HPLC and high-resolution mass spectrometry are complementary
Chromatography separates components under defined conditions. High-resolution mass spectrometry can support molecular-formula and sequence-related assignments for separated peaks. Tandem MS, amino-acid analysis, ion chromatography and other techniques may be needed depending on the suspected impurity.
Co-elution, unequal detector response and isomeric species mean no single method sees everything equally well.
Key points
- Stepwise synthesis can produce deletions, truncations, substitutions and stereochemical variants.
- Oxidation, deamidation and aggregation can develop later.
- Peptide-related and process-related impurities are different analytical questions.
- HPLC purity is method-dependent.
- Orthogonal characterization is stronger than one headline result.
What this article does not establish
This article does not identify an impurity in any AURAPEP lot, certify a manufacturing process or establish product safety, effectiveness, sterility or suitability for human use.
References
- Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963. https://doi.org/10.1021/ja00897a025
- Zeng K, et al. Liquid chromatography-high resolution mass spectrometry for peptide drug quality control. AAPS J. 2015. https://pubmed.ncbi.nlm.nih.gov/25716148/
- Li M, et al. Identification and accurate quantification of structurally related peptide impurities by LC-HRMS. Anal Bioanal Chem. 2018. https://pubmed.ncbi.nlm.nih.gov/29862433/
- Shi M, et al. Strategies for overcoming protein and peptide instability in biological formulations. Drug Discov Today. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10526705/